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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S28cell 5 (9%) and anaplastic 2 (4%). 19 cases were only reported as medul-
loblastomaWHO IV. Using immunohistochemical marker beta catenin and
histology 43 tumours were subdivided into WNT (26), SHH (13), non-
WNTnonSHH (4) groups.
Conclusion: There was an obvious male predominance in this group. 78%
of cases were diagnosed within 3 months of onset of symptoms. 57% of
cases had high risk disease.ST-1_V1.5
INFLAMMATORY MYOFIBROBLASTIC TUMORS: A TALE OF THREE
STORIES
J.H. Teo, M.Y. Chan, D.W.Q. Lian, R. Bhattacharyya, P. Iyer. Haematology and
Oncology Service, Department of Paediatric Subspecialties, KK Women's and
Children's Hospital, Singapore
Background/Objectives: Inﬂammatory myoﬁbroblastic tumors (IMT)
are unusual intermediate malignant potential tumors that occur in soft
tissues and visceral organs of children and young adults. The tumors
consist of myoﬁbroblastic spindle cells and inﬂammatory cells. These
tumors can be locally aggressive, recur or rarely metastasize. There are
no clear consensus guidelines on treatment for patients with such tu-
mors. We describe three cases from our tertiary academic paediatric
institute in Singapore.
Design/Methods: A retrospective analysis of paper, electronic records, and
histology slides of patients diagnosed with IMT in our hospital between
1997-2012 was performed.
Results: Three patients with IMT were identiﬁed. All patients had intra-
abdominal tumors (omentum, spleen, supra-renal) with one patient also
having a concurrent IMT located in the left hemi thorax. Histopathological
ﬁndings reported positivity for ALK -1 stain in 2 patients. Primary com-
plete surgical resection of the tumors was attempted without success.
And hence adjuvant chemotherapy was administered in all cases. A va-
riety of chemotherapeutic agents in combinations were used as per
physician preference. Two patients also received monotherapy with non-
steroidal anti-inﬂammatory drug (NSAID) when the tumors did not
respond to chemotherapy. Both the patients on NSAID therapy showed
transient partial responses. One patient with aggressive IMT died due to
neutropenic sepsis. The mTOR inhibitor sirolimus was started on one
patient who is now alive with stable disease three years after
commencement. A local recurrence in one patient was treated with
further surgery and she now remains in complete remission. These two
patients remain on active follow up.
Conclusion: Sirolimus appears to offer disease control in children with
inoperable or resistant IMT. Further studies are required to understand and
manage these fascinating mesenchymal tumors better.ST-1_V1.6
OUTCOMES OF SURGERY FOR RENAL TUMOURS WITH INTRAVASCULAR
EXTENSION
M. Bhagat, S. Qureshi, S. Kembhavi, T. Vora, M. Ramadwar,
G. Chinnaswamy, S. Laskar. Tata Memorial Hospital, Mumbai, India
Aim: The aim of this study was to review themanagement of childrenwith
Wilms' tumour who had intravascular thrombus.
Material and methods: The data regarding presentation, treatment
received, surgical management, complications and outcomes were evalu-
ated. All patients received neoadjuvant chemotherapy except in two.
Results: The study cohort included 31 patients with intravascular
thrombus treated from 2006 to 2015. The thrombus extent at presentation
was: Infrahepatic inferior vena cava (IVC) -19, retrohepatic IVC -6, supra-
hepatic IVC -1 and Atrium -5. There was complete clearance of IVC in 11/31
patients with neoadjuvant chemotherapy. Regression of the thrombus
occurred in 17/31 patients. Due to regression of the tumor thrombus from
the atrium, cardiopulmonary bypass could be avoided in 2 patients. In all
patients the thrombus had to be dissected off from the tunica intima due todense ﬁbrosis around it. The only major complication was massive
bleeding in one patient with atrial thrombus. There was no perioperative
or 30-day postoperative mortality. The 3-year OS and EFS was 89.3% and
77.8% respectively.
Conclusions: Intravascular tumor thrombus extension has favourable
outcomes after contemporary multidisciplinary treatment. Chemotherapy
aids in surgery, with tumor regression and thus may obviate the need of
cardiopulmonary bypass in atrial thrombus.ST-1_V1.7
PEDIATRIC MEDULLOBLASTOMA: EXPERIENCE AT TATA MEDICAL
CENTER, KOLKATA
Anirban Das, Rimpa Basu Achari, Shekhar Krishnan, Lateef Zameer, Aditi
Chandra, Mayur Parihar, Arpita Bhattacharyya. Tata Medical Center,
Kolkatta, India
Background: Medulloblastoma is the commonest pediatric malignant
brain tumor. Cure-rates of ~75% have been achieved in the West. Indian
centers have reported inferior survival. The aim of the studywas to analyze
the clinical proﬁle and outcome in children treated at a new referral cancer
hospital in Eastern India.
Methods: A retrospective analysis of case records of children (<18-
years) diagnosed with medulloblastoma, between June 2011-July 2016,
was performed. Modiﬁed Chang staging, using MRI of brain and spine,
and analysis of cerebrospinal ﬂuid was used. Children aged >3-years,
with post-operative residual tumor <1.5cm2, M0 stage, and non-large
cell/anaplastic histology, were classiﬁed as ‘standard-risk.’ ‘Standard-
risk’ and ‘high-risk’ children received cranio-spinal irradiation with
23.4Gy in 13 fractions, and 36Gy in 20 fractions, over 3.5-4 weeks,
respectively. Posterior fossa and/or tumor bed was boosted to a total
dose of 55.8Gy in 31 fractions. Following radiation, ‘standard-risk’
children received 8 cycles of cisplatin, lomustine and vincristine. ‘High-
risk’ patients received 8 cycles of cisplatin, cyclophosphamide and
vincristine, or, ifosfamide, cisplatin and etoposide (physician's discre-
tion). Analysis was performed using IBM-SPSSv20. Kaplan-Meier
method was used for survival analysis.
Results: Twenty-six children were enrolled. Median age was 6-years
(range:0.9-13.5); 4 (15.3%) were 3-years at diagnosis. 54% were males.
Median symptom-interval was 3.7-months (range: 1-12). Symptoms
included vomiting (20; 77%), headache (17; 65%), unsteadiness (14; 54%)
and cranial nerve palsy (2; 7%). Location of tumor (n¼22) included
midline, cerebellum (9; 41%), lateral cerebella (5; 23%) and roof of 4th
ventricle (8; 36%). Modiﬁed Chang staging: T (n¼17): T1 (1; 6%), T2 (2;
12%), T3 (5; 29%), T4 (9; 53%), and, M (n¼22): M0 (9; 41%), M1 (3; 13.5%),
M3 (7; 32%), M4 (3; 13.5%).
Seven (32%) childrenwere standard-risk and 15 (68%) were high-risk; data
was missing for the rest. Eight (31%) refused treatment. Extent of surgical
resection (n¼16) included gross total resection: 7 (44%), near total resec-
tion: 3 (18.5%), sub-total resection: 6 (37.5%). A ventriculo-peritoneal shunt
had been inserted in 11/20 (55%). Median time from surgery to initiation of
radiotherapy was 41-days (range:34-51).
At a median follow-up of 28.5-months (range:0.1-55), 12 (46.5%) were
alive, 9 (35%) of whom had completed, and 3 (11.5%) were on treatment; 3
(11.5%) had relapse/progression, 2 (7.5%) had abandoned treatment, while
1 (3.5%) had received palliative care. Among the 4 children3-years, 1 had
disease progression and 3 refused treatment. 4-year EFS (for those who
completed therapy was 66.1 ± 1.2%; standard-risk: 100%, high-risk: 45 ±
1.8%. Treatment-related complications included posterior fossa syndrome
(7; 39%), sepsis (4; 22%), shunt obstruction (1; 5%) and hearing loss (4;
22%).
Conclusion: Limitations of the study included high prevalence of treat-
ment-refusal/abandonment (10; 38%) and non-availability of molecular
subtyping for more accurate risk stratiﬁcation. Nevertheless, this study
shows that when properly diagnosed and treated, the outcomes of chil-
drenwith standard risk medulloblastoma in India are comparable with the
west. Further improvements in outcome require providing social support
to reduce treatment-refusal/abandonment, standardization of care for
